Cancer Gene Therapy Market Analysis In A New Research Study Now Available at ReportsnReports.com

ReportsnReports.com adds “Cancer Gene Therapy Market Analysis” report to its research database. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, TX (PRWEB) March 20, 2014

The gene therapy market has undergone a series of transformation from the initial days of research to the current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to its accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application of gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Browse complete report at http://www.reportsnreports.com/reports/276997-cancer-gene-therapy-market-analysis.html.

A major part of the cancer gene therapy product are currently in preclinical and Phase II of clinical trials. There has been a marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.

Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.

Place a direct purchase order at http://www.reportsnreports.com/purchase.aspx?name=276997. Also, inquire for DISCOUNT offered on this research study at http://www.reportsnreports.com/contacts/discount.aspx?name=276997.

Cancer Gene Therapy Report Highlights & Findings:

  •     Cancer Gene Therapy Drugs in Pipeline: More Than 60
  •     Highest Number of Drugs in Preclinical Stage: 37
  •     Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100
  •     Significance of Oncology Therapeutics in Gene Therapy
  •     Current Applications of Gene Therapy to Cancer Treatment
  •     Favorable Parameters for Cancer Gene Therapy
  •     Issued Involved with Application of Gene Therapy in Cancer Patients
  •     Regulatory Scenario for Gene Therapy Market
  •     Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

Table of Contents
1. Introduction to Gene Therapy
2. Global Gene Therapy Market
3. Significance of Cancer Therapeutics in Gene Therapy
4. Current Applications of Gene Therapy to Cancer Treatment
5. Cancer Gene Therapy Market Dynamics
6. Regulatory Scenario for Gene Therapy Market
7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
8. Marketed Cancer Gene Therapy Drugs
9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline
10. Competitive Landscape

List of Figures

About Us:
ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.


Contact